Acute Gout Flare Treatment
For a patient experiencing an acute gout flare, initiate treatment immediately with one of three first-line options: low-dose colchicine (1.2 mg followed by 0.6 mg 1 hour later), NSAIDs (any NSAID at full anti-inflammatory dose), or corticosteroids (oral, intramuscular, or intra-articular), selecting based on the patient's comorbidities and contraindications 1, 2.
First-Line Treatment Options
The choice among these three equally effective options depends on patient-specific factors:
Colchicine (Preferred if no contraindications)
- Dose: 1.2 mg followed by 0.6 mg one hour later 1
- This low-dose regimen is as effective as higher doses but causes significantly fewer gastrointestinal side effects 1
- Contraindicated in patients with:
- Renal impairment (CKD stage ≥3)
- Hepatic dysfunction
- Concurrent use of strong CYP3A4 inhibitors or P-glycoprotein inhibitors 1
- Common adverse effects: diarrhea, nausea, vomiting, abdominal cramping 1
NSAIDs (Good alternative, especially if colchicine contraindicated)
- Any NSAID at full anti-inflammatory dose is appropriate 1, 2
- Indomethacin has no superiority over other NSAIDs (naproxen, ibuprofen) despite traditional preference 1
- Contraindicated in patients with:
- Renal disease
- Heart failure
- Cirrhosis
- History of GI bleeding/ulcers 1
Corticosteroids (Best for patients with multiple contraindications)
- Oral, intramuscular, or intra-articular routes all effective 2, 3
- Particularly useful in elderly patients with multiple comorbidities who cannot tolerate colchicine or NSAIDs 3
- Safer in renal impairment compared to other options
Critical Timing Consideration
Start treatment as soon as possible after flare onset—early intervention provides better pain relief and faster resolution 2, 4.
What About Urate-Lowering Therapy During the Flare?
If the patient is already on urate-lowering therapy (ULT), continue it during the flare 5.
If considering initiating ULT for the first time, you may start it during the acute flare rather than waiting for resolution, though this is a conditional recommendation 5. The 2020 ACR guideline shifted away from the older paradigm of mandatory flare resolution before ULT initiation.
Refractory Cases
For flares that fail to respond to standard therapies, IL-1 inhibitors (anakinra, canakinumab) are established options 2, 4, particularly valuable in patients with severe renal disease where other options are limited 6.
Common Pitfalls to Avoid
- Don't use high-dose colchicine regimens—they increase toxicity without improving efficacy 1
- Don't assume indomethacin is superior—any NSAID works equally well 1
- Don't delay treatment waiting for diagnostic confirmation if clinical presentation is classic
- Don't stop existing ULT during a flare—this can prolong the episode 5
- Don't forget to assess renal function before choosing colchicine or NSAIDs 1, 3